Home > Insider Trading > Chemomab Therapeutics Ltd. > Profile

Chemomab Therapeutics Ltd. (CMMB)

Market is closed

Sector: Pharmaceutical Preparations

Related Insiders

Nissim Darvish, Director, 2023-07-05
M. Jill Quigley, Director, 2023-06-20
Sigal Fatal, Chief Financial Officer, 2023-06-16

Nissim Darvish, Director, 2023-07-05
M. Jill Quigley, Director, 2023-06-20
Sigal Fatal, Chief Financial Officer, 2023-06-16
Charles Alan Moses, Director, 2023-03-23
Claude Nicaise, Director, 2023-03-23
Harris Neil Cohen, Director, 2023-03-23
Partnership Limited Gp Biofund Israel Orbimed, Large Shareholder, 2023-01-05
Ltd. Gp Israel Orbimed, Large Shareholder, 2023-01-05
Adi George Mor, Chief Scientific Officer, 2023-01-05
Bejosa Matthew Frankel, Chief Medical Officer, 2022-11-15
Donald Marvin, Executive Vp, Cfo & Coo, 2022-06-21
Michael Joel Maryles, Director, 2022-05-25
R Dale Pfost, Chief Executive Officer, 2022-03-15
P Stephen Squinto, Director, 2021-04-21
Arnon Aharon, Chief Medical Officer, 2021-03-25
Peter Thiel, Large Shareholder, 2021-03-19
Stanislav Polovets, Director, 2021-03-12
Andrew Fine, Chief Financial Officer, 2021-03-11
J. Stephen Dipalma, Chief Financial Officer, 2020-05-07
Ofer Gonen, Director, 2020-01-02
Access Industries, Llc, Other, 2020-01-02
Access Industries Management, Llc, Other, 2020-01-02
Ltd. Industries Biotechnology Clal, Large Shareholder, 2020-01-02
Access Industries Holdings Llc, Large Shareholder, 2020-01-02
Len Blavatnik, Other, 2020-01-02
L Reginald Hardy, Director, 2020-01-02
Ruth Alon, Director, 2020-01-02
Jonathan Burgin, See Remarks, 2020-01-02
T Dennison Veru, Director, 2020-01-02
Frank Haluska, Chief Executive Officer, 2020-01-02
Michal Ohev-Zion Gilon, Vp, Research And Development, 2020-01-02
Salar Roshan, Head Of Business Development, 2020-01-02
T Sean Daly, Vp, Clinical Operations, 2020-01-02
Ron Knickerbocker, See Remarks, 2020-01-02
T. Isaac Kohlberg, Director, 2020-01-02
Efrat Makov, Director, 2020-01-02
David Kerstein, Chief Medical Officer, 2020-01-02
Lawrence Howard, Director, 2020-01-02
Ltd. Management Capital Gabriel, Large Shareholder, 2019-12-31

Show All Insiders (39)

Hedge Fund Popularity

Display

Display Share Price

Display Large Version

Hedge Fund Holdings

Filing Period:

Last updated on May 15, 2025, 4:23 pm based on SEC 13F filings Last update: May 15, 2025, 4:23 pm

No.	Hedge Fund	Shares	Value	Activity	% Port
1.	OrbiMed Advisors Samuel Isaly	1,741,273	$1,897,988		0.05%
2.	Sphera Global Healthcare Fund Doron Breen And Mori Arkin	900,428	$981,467	-26%	0.23%
3.	Ikarian Capital Neil Shahrestani	213,052	$232,226		0.03%

Insider Trading: Purchases See All

Insider	Price	Amount	Total Value	Remaining Holdings	Date	Form 4
Marvin Officer	$3.25	250	$812.50	2,000	2022-03-16	Filing
Marvin Officer	$3.30	250	$825.00	1,750	2022-03-16	Filing
Maryles Director	$2.76	33	$91.08	1,433	2022-05-24	Filing
Maryles Director	$2.89	400	$1,156.00	1,400	2022-05-24	Filing
Cohen Director	$3.19	2,000	$6,380.00	12,409	2022-05-18	Filing

Insider Trading: Sales See All

Insider	Price	Amount	Total Value	Remaining Holdings	Date	Form 4
Orbimed Large Shareholder	$4.51	70,524	$318,063.24	2,241,274	2023-01-03	Filing
Orbimed Large Shareholder	$3.34	266,376	$889,695.84	2,311,798	2023-01-03	Filing
Mor Officer, Director	$5.03	6,100	$30,663.48	251,147	2023-01-03	Filing
Mor Officer, Director	$5.03	7,700	$38,706.36	317,075	2023-01-03	Filing
Cohen Director	$2.00	2,409	$4,818.00	10,000	2022-11-16	Filing

Institutional Investors' Holdings

Filing Period:

No.	Name	Shares	Value	% Port
1.	Yelin Lapidot Holdings Management Ltd.	578,291	$630,337	0.12%
2.	Morgan Stanley	117,160	$127,704	0%
3.	Kestra Private Wealth Services, Llc	31,241	$34,053	0%
4.	Boothbay Fund Management, Llc	26,189	$28,546	0%
5.	Rhumbline Advisers	23,849	$25,989	0%

News See All

Click here to See All News

Chemomab Therapeutics Ltd. (CMMB)

Related Insiders

Hedge Fund Popularity

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Call Transcript

5 Worst Stock Picks of Cathie Wood